Search Results
FREEDOM-1: A New Frontier in Living Donor Kidney Transplant
Freedom -1 Clinical Trial for Kidney Transplant Patients
FREEDOM-1 Clinical Trial for Patients Preparing for Kidney Transplant (November 17, 2020)
Talaris Therapeutics’ Presentation for the Alport Syndrome Foundation Webinar
Ch. 6: FREEDOM-2 Phase 2 Trial with FCR001, Designed to Induce Immune Tolerance in LDKT Recipients
FCR001, an investigational cell therapy: Harnessing the power of immune tolerance in LDKT for HCP
Talaris Presentation at the 2022 Tandem Transplantation and Cellular Therapy Meeting
Talaris Presentation at the 2022 Cutting Edge of Transplantation (CEoT) Transplant Summit
FREEDOM-3: A Quest for a Future Restored from Diffuse Scleroderma
Innovation in Kidney Transplantation and Post-care (Talaris Therapeutics)
Donor and Recipient Coordinators
2 Pharmaceutical IPOs Going Public May 7, $VISN Gyroscope Therapeutics, Talaris Therapeutics $TALS